LLY - Lilly Incyte's baricitinib shows hair regrowth in late-stage alopecia areata study

Eli Lilly (LLY) and Incyte (INCY) announce top-line results from Phase 3 BRAVE-AA2 study, evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata ((AA)).Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to placebo.AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.BRAVE-AA2 is the first Phase 3 study with positive results in AA. Data from an additional late-stage study will be available in H1.Detailed results will be presented at an upcoming conference and published in a peer-reviewed journal later this year.

For further details see:

Lilly, Incyte's baricitinib shows hair regrowth in late-stage alopecia areata study